Assort Health Series C Funding Led by Menlo Ventures

In a significant move to streamline patient access within the healthcare industry, Assort Health has successfully closed its Series C funding round, led by prominent venture capital firm Menlo Ventures. This investment underscores the growing demand for intelligent solutions that address the persistent inefficiencies at the front door of medical practices.

For years, the operational backbone of patient scheduling and intake has relied on fragmented systems and manual processes, often encapsulated in physical binders and tribal knowledge. This antiquated approach leads to significant administrative burdens, estimated to consume a substantial portion of U.S. healthcare expenditures, and results in patient frustration through long wait times and incorrect specialist referrals. Assort Health is tackling this challenge head-on by deploying an AI-powered platform designed to create a seamless and personalized patient journey.

The company's innovative technology moves beyond simple digital replacements. It establishes a 'Patient Journey Memory,' an intelligent system that learns from every interaction, anticipates future needs, and ensures continuity of care. This capability is particularly vital in complex specialties like orthopedics, where Assort Health initially focused, and has since expanded its reach to dermatology, cardiology, OB-GYN, and dentistry, among others. The platform's ability to absorb institutional knowledge and retain patient history makes it an invaluable asset for healthcare providers.

Menlo Ventures, known for its deep expertise in enterprise AI and healthcare technology, recognized the transformative potential of Assort Health. The firm's recent report highlighted patient engagement and front-office operations as a prime area for AI investment within health systems. This conviction is shared by the firm's partners, including JP Sanday, Matt Murphy, Greg Yap, Derek Xiao, and Sam Borja, who are backing the company's vision to create a more accessible and efficient healthcare ecosystem. The leadership of Assort Health, co-CEOs Jon Wang and Jeffery Liu, brings a unique blend of AI research acumen and deep healthcare operational experience, having spent extensive time understanding the intricacies of practice management.

With over 180 million patient interactions processed across numerous specialties, Assort Health has demonstrated its platform's scalability and effectiveness. This extensive data accumulation continuously refines the underlying AI models, leading to more accurate scheduling, proactive outreach for care gaps, and improved revenue cycle management. The company's success aligns with Menlo Ventures' broader investment thesis in companies that demonstrably expand access, enhance patient outcomes, and reduce healthcare costs, a philosophy also reflected in their support for portfolio companies like Grow Therapy, Nourish, and Solace.

This Series C funding will enable Assort Health to further accelerate its product development, expand its market reach, and solidify its position as a leader in healthcare access technology. By optimizing the crucial first point of contact, Assort Health is not just improving administrative workflows but fundamentally enhancing the patient experience, ensuring that the front door of healthcare remains open and welcoming.